文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

奥密克戎变异株感染诱导的有限交叉免疫,未接种疫苗者尤其如此。

Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination.

机构信息

Gladstone Institutes, San Francisco, CA, USA.

Biomedical Sciences Graduate Program, University of California, San Francisco, San Francisco, CA, USA.

出版信息

Nature. 2022 Jul;607(7918):351-355. doi: 10.1038/s41586-022-04865-0. Epub 2022 May 18.


DOI:10.1038/s41586-022-04865-0
PMID:35584773
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9279157/
Abstract

SARS-CoV-2 Delta and Omicron are globally relevant variants of concern. Although individuals infected with Delta are at risk of developing severe lung disease, infection with Omicron often causes milder symptoms, especially in vaccinated individuals. The question arises of whether widespread Omicron infections could lead to future cross-variant protection, accelerating the end of the pandemic. Here we show that without vaccination, infection with Omicron induces a limited humoral immune response in mice and humans. Sera from mice overexpressing the human ACE2 receptor and infected with Omicron neutralize only Omicron, but not other variants of concern, whereas broader cross-variant neutralization was observed after WA1 and Delta infections. Unlike WA1 and Delta, Omicron replicates to low levels in the lungs and brains of infected animals, leading to mild disease with reduced expression of pro-inflammatory cytokines and diminished activation of lung-resident T cells. Sera from individuals who were unvaccinated and infected with Omicron show the same limited neutralization of only Omicron itself. By contrast, Omicron breakthrough infections induce overall higher neutralization titres against all variants of concern. Our results demonstrate that Omicron infection enhances pre-existing immunity elicited by vaccines but, on its own, may not confer broad protection against non-Omicron variants in unvaccinated individuals.

摘要

SARS-CoV-2 的 Delta 和奥密克戎变异株是全球关注的重要变异株。虽然感染 Delta 的个体有发生重症肺部疾病的风险,但感染奥密克戎通常会引起较轻的症状,尤其是在接种疫苗的个体中。那么问题来了,广泛的奥密克戎感染是否会导致未来的交叉变异保护,从而加速大流行的结束。在这里,我们发现,在没有接种疫苗的情况下,奥密克戎感染在小鼠和人类中诱导了有限的体液免疫反应。来自过表达人 ACE2 受体并感染奥密克戎的小鼠的血清仅能中和奥密克戎,而不能中和其他关注变异株,而在感染 WA1 和 Delta 后则观察到更广泛的交叉变异株中和作用。与 WA1 和 Delta 不同,奥密克戎在感染动物的肺部和大脑中复制水平较低,导致疾病较轻,促炎细胞因子表达减少,肺驻留 T 细胞激活减少。未接种疫苗并感染奥密克戎的个体的血清也表现出对奥密克戎本身的有限中和作用。相比之下,奥密克戎突破性感染会引起针对所有关注变异株的更高中和抗体滴度。我们的研究结果表明,奥密克戎感染增强了疫苗引发的固有免疫,但单独感染奥密克戎本身可能无法为未接种疫苗的个体提供针对非奥密克戎变异株的广泛保护。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/76c3cdbc483b/41586_2022_4865_Fig13_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/e1da23af0a5d/41586_2022_4865_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/a5663d79f0a9/41586_2022_4865_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/09ca2b33bee2/41586_2022_4865_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/46a585386930/41586_2022_4865_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/441d494d4b9d/41586_2022_4865_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/99f0b6247269/41586_2022_4865_Fig6_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/9a74d4578599/41586_2022_4865_Fig7_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/ae224c8b2f29/41586_2022_4865_Fig8_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/c980c3dfccba/41586_2022_4865_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/c51940b8e006/41586_2022_4865_Fig10_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/55f5d62505cb/41586_2022_4865_Fig11_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/86324f03c427/41586_2022_4865_Fig12_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/76c3cdbc483b/41586_2022_4865_Fig13_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/e1da23af0a5d/41586_2022_4865_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/a5663d79f0a9/41586_2022_4865_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/09ca2b33bee2/41586_2022_4865_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/46a585386930/41586_2022_4865_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/441d494d4b9d/41586_2022_4865_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/99f0b6247269/41586_2022_4865_Fig6_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/9a74d4578599/41586_2022_4865_Fig7_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/ae224c8b2f29/41586_2022_4865_Fig8_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/c980c3dfccba/41586_2022_4865_Fig9_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/c51940b8e006/41586_2022_4865_Fig10_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/55f5d62505cb/41586_2022_4865_Fig11_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/86324f03c427/41586_2022_4865_Fig12_ESM.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d920/9279157/76c3cdbc483b/41586_2022_4865_Fig13_ESM.jpg

相似文献

[1]
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination.

Nature. 2022-7

[2]
Limited Cross-Variant Immunity after Infection with the SARS-CoV-2 Omicron Variant Without Vaccination.

medRxiv. 2022-2-9

[3]
Omicron infection enhances Delta antibody immunity in vaccinated persons.

Nature. 2022-7

[4]
Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone.

Int J Mol Sci. 2022-7-12

[5]
Delta Infection After Vaccination Elicits Potent Neutralizing Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron.

J Infect Dis. 2022-11-1

[6]
Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost.

Emerg Microbes Infect. 2022-12

[7]
A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.

Elife. 2022-8-25

[8]
Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants.

Cell. 2022-4-28

[9]
Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals.

mBio. 2022-4-26

[10]
Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection.

Nat Commun. 2022-2-9

引用本文的文献

[1]
Mouse Adapted Omicron BA.5 Induces A Fibrotic Lung Disease Phenotype in BALB/c Mice.

bioRxiv. 2025-7-16

[2]
The roles of macrophages and monocytes in COVID-19 Severe Respiratory Syndrome.

Cell Insight. 2025-5-8

[3]
Monitoring of antibodies against SARS-CoV-2 over 2 years and characterization of immune responses following Omicron infection in a South Indian community cohort.

Sci Rep. 2025-7-9

[4]
Coordinated early immune response in the lungs is required for effective control of SARS-CoV-2 replication.

Nat Commun. 2025-6-25

[5]
The immunological impact of revaccination in a hybrid-immune world.

Front Immunol. 2025-6-9

[6]
Neuroendocrine cells orchestrate regeneration through Desert hedgehog signaling.

Cell. 2025-6-3

[7]
Mass Cytometry Analysis of High-Dimensional Single-Cell Immune Profiles in ZF2001-Vaccinated Patients Infected with SARS-CoV-2.

Infect Drug Resist. 2025-5-14

[8]
Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages.

Signal Transduct Target Ther. 2025-1-27

[9]
Characterization of Vaccine-Enhanced Humoral Immune Responses Against Emergent SARS-CoV-2 Variants in a Convalescent Cohort.

Pathogens. 2025-1-8

[10]
Modelling COVID-19 mutant dynamics: understanding the interplay between viral evolution and disease transmission dynamics.

R Soc Open Sci. 2024-10-30

本文引用的文献

[1]
Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles.

Proc Natl Acad Sci U S A. 2022-8-2

[2]
Reduced pathogenicity of the SARS-CoV-2 omicron variant in hamsters.

Med. 2022-4-8

[3]
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa.

Science. 2022-5-6

[4]
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.

Med. 2022-4-8

[5]
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.

Nature. 2022-3

[6]
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant.

Nature. 2022-3

[7]
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.

Cell. 2022-2-3

[8]
The omicron (B.1.1.529) SARS-CoV-2 variant of concern does not readily infect Syrian hamsters.

Antiviral Res. 2022-2

[9]
Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study.

Lancet. 2022-1-29

[10]
Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron.

Nature. 2022-3

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索